Osteoporotic fractures pose an enormous public health problem, and a variety of interventions will be needed to reduce their impact. The only rationale for risk assessment is to employ these interventions efficiently. However, screening tests have costs and the long-term benefits of treatment may be uncertain. This creates a need to consider the costs of risk assessment and the costs of treatment as well as the costs of fractures that might be averted.
KeywordsBone Mineral Density Fracture Risk Hormone Replacement Therapy Osteoporotic Fracture Estrogen Replacement Therapy
Unable to display preview. Download preview PDF.
- Eddy D, Cummings SR, Dawson-Hughes B, Johnston CC, Lindsay R, Melton LJ HI, Slemenda C. (in press) Guidelines for the prevention, diagnosis and treatment of osteoporosis: Cost-effectiveness analysis and review of the evidence. Osteoporosis Int. Google Scholar
- Torgerson DJ, Kanis JA. (1995) Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. Q J Med 88: 135–139.Google Scholar
- U.S. Congress, Office of Technology Assessment. (1995) Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Volume I: Cost-Effectiveness Analysis, OTA-BP-H-160. U.S. Government Printing Office, Washington, DC.Google Scholar
- U.S. Congress, Office of Technology Assessment. (1995) Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Volume II: Evidence on Benefits, Risks, and Costs. OTA-BP-H-144. U.S. Government Printing Office, Washington, DC.Google Scholar